|
|
400 4th Avenue
Belmar, NJ 07719 USA
phone:(732) 280-1596
fax:(973) 643-4502
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.acquisci.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| identifies, acquires and develops undervalued and promising emergent medical technologies to commercial fruition. |
|
| Management |
|
| |
|
|
| |
|
| Keywords |
| Clinical, Medical device, anti-flammatory treatment, cardiovascular, heart failure |
|
|
|
| Description |
|
Acquisci, Inc. is a privately held company that has recently acquired a device-based propriety multi-therapeutic platform; doseable-Oxidative Stressed Autologuous Blood (d-OSAB), a systemic anti-flammatory treatment of cardiovascular diseases wherein inflammation is an underlying etiology. |
|
| Products / Services |
The Company's initial clinical inflammatory-based target are Ischemic Brain Stroke and Chronic Heart Failure, two diseases with few viable treatment options. d-OSAB represents a novel re-engineered formulation based on unregulated traditional therapies, which have been in use for more than 20 years and generated a safety profile of non-toxicity in more than five million treatments delivered to more than 35,000 patients. However, previous therapies utilized imprecise technologies not suitable for FDA or European regulatory clearance for commercial marketing. d-OSAB includes a regulatory-approvable patent pending therapeutic contract device, among other proprietary advantages, allowing for precise dose measurement and control. Additional applications of the d-OSAB platform include a purification process for the production of pathogen-free biologics, most notably inactivating infectious prions, the rogue protein attributed to Mad Cow and Creutfeldt-Jakob diseases.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members